evo真人视讯

Shenzhen Cell Valley Biopharmaceutical Co., Ltd. is a CRO/CDMO service provider specializing in China’s cell and gene therapy industry. It is among the first domestic enterprises with GMP-compliant production capabilities for clinical-grade retroviral vectors and is part of Shenzhen’s “20+8” strategic emerging industries initiative.

The company provides GMP-grade production of cellular products including CAR-T, CAR-NK, CAR-M, γδT, TIL, and TCR-T, as well as viral vectors such as RVV, LVV, and AAV. Its capabilities also cover non-viral vectors and therapeutic materials including exosomes, antibodies, cytokines, oncolytic viruses, and vaccines.